FDA finds deficiencies in Mylan’s generic Advair; shares fall


(Reuters) – Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline’s blockbuster inhaled lung drug Advair for the second time, as they found “minor deficiencies” in the treatment.

FILE PHOTO: A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason Reed/File Photo

Shares of Mylan fell 4.5 percent to $39.80 after the bell.

Mylan did not provide details on the nature of the deficiencies cited by the U.S. Food And Drug Administration and it remains unclear…



Read More Here

Be the first to comment on "FDA finds deficiencies in Mylan’s generic Advair; shares fall"

Leave a comment

Your email address will not be published.


*